NCT01765790View on ClinicalTrials.gov

Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

June 14, 2012

Primary Completion Date

July 28, 2016

Study Completion Date

July 28, 2016

Conditions
Metastatic Adenocarcinoma of the Colon or RectumMalignant Solid Tumors
Interventions
BIOLOGICAL

Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody

"* Dosing every 2 weeks~* Intravenous injection"

BIOLOGICAL

Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody

"* Dosing weekly~* Intravenous injection"

Trial Locations (5)

34232

Florida Cancer Specialists / Sarah Cannon Research Institute, Sarasota

69120

Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg, Heidelberg

77030

Department of Investigator Cancer Therapeutics, University of Texas, MD Anderson Cancer Center, Houston

78229

Cancer Therapy and Research Center (CTRC), The University of Texas Health Science Center at San Antonio, San Antonio

85258

Scottsdale Healthcare, Scottsdale

All Listed Sponsors
lead

Baxalta now part of Shire

INDUSTRY

NCT01765790 - Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors | Biotech Hunter | Biotech Hunter